2026 ASRM Guidelines: Should You Get ICSI Even With Normal Sperm?

The 2026 updated ASRM committee opinion clarifies when non-male-factor ICSI is justified and was created to solve fertilization problems caused by poor-quality sperm. Below we cover the evidence and practical talking points for your fertility consultation.

This article is not intended to second-guess clinical providers. Its goal is to unpack the reasoning behind ICSI recommendations, so you can hold a fully informed discussion at your next consultation.

What Is ICSI, and What Was It Designed For?

In conventional IVF-insemination, eggs and sperm are placed together inside a lab dish to allow natural fertilization. ICSI (intracytoplasmic sperm injection) works differently: an embryologist selects one single sperm and injects it directly inside an egg.

ICSI first entered clinical use to address severe male-factor infertility. When sperm count is extremely low, motility is poor, or morphology is heavily abnormal, sperm cannot achieve fertilization on their own, and ICSI bypasses that physical barrier.

ICSI was developed to address fertilization failure; however, it was not designed to improve inherent embryo quality. It is one of the core opinions in the 2026 guideline. If fertilization itself is not your limiting factor, ICSI will most likely provide no additional benefit.

When Is ICSI Clearly Justified

There are well-supported clinical scenarios where ICSI is appropriate:

1. Severe male-factor infertility: Very low sperm count, poor motility, or severe morphological defects that make conventional fertilization unlikely.

2. Prior fertilization failure: Very low or total fertilization failure in an earlier conventional-insemination IVF cycle.

3. PGT-M (preimplantation genetic testing for monogenic disorders): ICSI prevents stray extraneous sperm DNA from contaminating genetic test results.

4. Frozen-thawed oocytes: Freeze-thawing may harden the egg’s outer shell (zona pellucida), making ICSI the standard laboratory approach.

All these cases share one feature: fertilization itself is the bottleneck, exactly the problem ICSI was designed to solve.

When Does ICSI Fail to Improve Live-Birth Outcomes for Non-Male-Factor

This section captures the most important guidance from the 2026 ASRM committee opinion. For people with normal semen, research does not show higher live-birth rates with ICSI across these frequent clinical situations:

1. Unexplained infertility. Some trials observe higher fertilization rates with ICSI, yet no study has translated that into improved live‑birth outcomes.

2. Low ovarian reserve / few retrieved eggs. Some clinicians suggest ICSI can secure fertilization for every egg and improve cycle efficiency when few eggs are retrieved. However, clinical trials lack clear evidence for this benefit.

3. Advanced maternal age. In clinical practice, fertilization rates for people over 35 remain comparable to younger patients using standard insemination.

4. PGT-A: ASRM guidance explicitly states that routine ICSI for all PGT-A cycles fails to improve euploidy rates, live-birth rates, or the total number of usable embryos.

In all four scenarios, fertilization is not the primary limiting factor. Obstacles may lie in embryo development, uterine receptivity, or other biological areas, none of which ICSI can correct.

Why Do Clinicians Still Recommend ICSI Despite the Evidence?

ICSI utilisation keeps climbing in real-world practice, even when male-factor issues are absent. U.S. registry data shows overall ICSI use rose from 36.4 % (1996) up to 76.2 % (2012). Among non-male-factor patients, usage jumped from 15 % to 67 % over that same period.

What drives this gap between clinical evidence and everyday practice? A 2026 multi-centre survey in the Journal of Obstetrics and Gynaecology Canada provides context: most patients have no strong pre-existing ICSI preference, and 55 % simply follow their provider’s recommendation.

Providers suggest ICSI for two broad sets of reasons

1. Evidence-based indications: Prior total fertilization failure, PGT-M and other confirmed fertilisation-related risks.

2. Risk-averse reasoning: Risk-averse reasoning: When egg numbers are low or egg quality seems suboptimal, clinicians may opt for ICSI to prevent complete fertilization failure and having no embryos for transfer. Though this precautionary strategy lacks strong supporting clinical evidence.

It is also important to acknowledge: clinicians carry real psychological pressure to prevent total fertilization failure. This stress shapes real-world decision-making.

What This Means for You

If your semen analysis is normal and ICSI is being proposed for your cycle, you can actively inquire about your sperm condition and whether it is appropriate for performing ICSI.

Per the 2026 ASRM committee opinion, if your situation is unexplained infertility, diminished ovarian reserve, advanced maternal age, or planned PGT-A, the answer will most likely be no.

ICSI is not a “better, upgraded” fertilization technique. It solves a narrow set of fertilisation-related problems. 

Where semen parameters are normal, conventional insemination and ICSI deliver comparable live-birth odds, while ICSI adds extra laboratory steps and incremental costs to your IVF cycle.

Understanding guideline background helps you hold balanced conversations rather than simply accepting a recommendation at face value.

The Bottom Line

The core message of the 2026 ASRM guidance is straightforward: ICSI belongs where fertilisation problems actually exist, not as a default add-on. For patients with normal semen results, ICSI does not improve live-birth outcomes in most non-male-factor scenarios.

If you are preparing for IVF, take time to discuss the explicit rationale behind any ICSI suggestion. Familiarity with clinical-guideline context empowers you to make well-informed reproductive decisions.

Have questions comparing fertilization options for your IVF cycle? Connect with the CEF fertility team. Email info@cefivf.com or visit our Contact page.

Disclaimer: This educational blog summarises the 2026 ASRM Committee Opinion for ICSI in non-male-factor indications. It is not personalised medical advice. All fertility-treatment decisions should be discussed with a licensed reproductive-endocrinology specialist.